Neurogene Q2 adjusted loss per share misses estimates on employee costs

Neurogene

11/08/2026 12:39

Overview
US biotech for rare neurological diseases reported Q2 adjusted loss per share missed analyst expectations
Net loss and operating expenses increased yr/yr due to higher NGN-401 development costs
Company extended cash runway into Q1 2029 with $144 mln oversubscribed financing

Outlook
Company expects to complete BLA-enabling PPQ runs by year-end 2026
Topline data from Embolden registrational trial anticipated in 2H 2027
Company expects current cash resources to fund operations into 1Q 2029

Result Drivers
NGN-401 DEVELOPMENT COSTS - Higher R&D expenses driven by NGN-401 clinical trial and manufacturing activities
EMPLOYEE-RELATED EXPENSES - Increased non-cash stock-based compensation and employee costs contributed to higher R&D and G&A expenses
PRE-COMMERCIAL ACTIVITIES - G&A expenses rose due to corporate and pre-commercial activities and higher professional fees

Company press release: ID:nBw9VcmHma

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Adjusted Loss Per Share
Miss
$1.53
$1.42 (9 Analysts)
Q2 Net Loss
 
$34.49 mln
 
Q2 Operating Expenses
 
$36.67 mln
 
Q2 Operating Income
 
-$36.67 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Neurogene Inc is $69.00, about 88.8% above its August 10 closing price of $36.55

Reuters Recommended Reads
Aug 10 - Biotech firm Nkarta posts Q2 net loss; cash runway into 2029
Aug 10 - CervoMed Q2 net loss lower than estimates as costs drop
Aug 11 - Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)